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Detecting  β-lactamase–mediated carbapenem resist-
ance among  Klebsiella pneumoniae isolates and other
Enterobacteriaceae is an emerging problem. In this study,
15 blaKPC-positive Klebsiella pneumoniae that showed dis-
crepant results for imipenem and meropenem from 4 New
York City hospitals were characterized by isoelectric focus-
ing; broth microdilution (BMD); disk diffusion (DD); and
MicroScan, Phoenix, Sensititre, VITEK, and VITEK 2 auto-
mated systems. All 15 isolates were either intermediate or
resistant to imipenem and meropenem by BMD; 1 was sus-
ceptible to imipenem by DD. MicroScan and Phoenix report-
ed 1 (6.7%) and 2 (13.3%) isolates, respectively, as
imipenem susceptible. VITEK and VITEK 2 reported 10
(67%) and 5 (33%) isolates, respectively, as imipenem sus-
ceptible. By Sensititre, 13 (87%) isolates were susceptible
to imipenem, and 12 (80%) were susceptible to meropen-
em. The VITEK 2 Advanced Expert System changed 2
imipenem MIC results from >16 µg/mL to <2 µg/mL but kept
the interpretation as resistant. The recognition of carbapen-
em-resistant K. pneumoniae continues to challenge auto-
mated susceptibility systems.
C
arbapenem resistance among the Enterobacteriaceae
is emerging in the United States, particularly on the
East Coast (1–6). Resistance to the most widely used car-
bapenems, i.e., imipenem and meropenem, can be mediat-
ed by a variety of mechanisms, including β-lactamases,
porin changes, and changes in penicillin-binding proteins
(1,7,8). KPC enzymes are among the most common β-lac-
tamases mediating carbapenem resistance among isolates
of Enterobacteriaceae (1–6). KPC enzymes are class A
β-lactamases that mediate resistance to extended-spectrum
cephalosporins in addition to carbapenems; these β-lacta-
mases are usually plasmid encoded.
Clinical microbiology laboratories have often found it
difficult to achieve accurate susceptibility testing results
for carbapenem drugs. Early studies documented false
resistance to imipenem due to degradation of the drug (9);
later studies with the VITEK system (bioMérieux,
Durham, NC, USA) demonstrated false resistance, specif-
ically with Proteus mirabilis (10). Several recent profi-
ciency testing studies have shown problems of both false
resistance and false susceptibility with imipenem and
meropenem among a variety of enteric species (11,12).
Even quality control measures fail to detect all false resist-
ance problems (13).
Yigit and colleagues described the KPC-1 β-lactamase
in 2001 (1). The β-lactamase was identified in an imipen-
em-resistant isolate of Klebsiella pneumoniae from the
United States. Subsequently, 3 additional KPC-type β-lac-
tamases have been described from Salmonella, K. oxytoca,
Enterobacter cloacae, and other K. pneumoniae; these dif-
fer in amino acid sequence from each other, typically by 1
or 2 amino acids (2–6). Bratu and colleagues reported false-
susceptible results for K. pneumoniae isolates with the
MicroScan WalkAway system (Dade MicroScan, Inc., West
Sacramento, CA, USA), which were attributed in part to
low inoculum size (14). Similar problems with false-sus-
ceptible results were noted with the VITEK system (15).
The goal of this study was to conduct a rapid assessment of
currently available antimicrobial susceptibility testing
methods to determine whether these methods were capable
of consistently detecting KPC-mediated carbapenem resist-
ance in fresh clinical isolates of K. pneumoniae.
Carbapenem Resistance in
Klebsiella pneumoniae Not
Detected by Automated
Susceptibility Testing
Fred C. Tenover,* Rajinder K. Kalsi,† Portia P. Williams,‡ Roberta B. Carey,* Sheila Stocker,* 
David Lonsway,* J. Kamile Rasheed,* James W. Biddle,* John E. McGowan Jr.,‡ and Bruce Hanna†
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 8, August 2006 1209
*Centers for Disease Control and Prevention, Atlanta, Georgia,
USA; †Bellevue Hospital, New York, New York, USA; and ‡Rollins
School of Public Heath, Emory University, Atlanta, Georgia, USAMaterials and Methods
Bacterial Isolates
To achieve a diversity of β-lactam resistance pheno-
types, we selected 15 isolates of K. pneumoniae from 4
hospitals in New York City, all serviced by a central micro-
biology laboratory, on the basis of varying susceptibility
patterns to imipenem, meropenem, and extended-spectrum
cephalosporins. The isolates were from a variety of body
sites (blood, sputum, and urine) and obtained in a 1-month
period in 2005. The carbapenem-resistant quality control
isolates K. pneumoniae 1534 (containing the KPC-1 car-
bapenemase) and Serratia marcescens 525 (which con-
tains an SME-like β-lactamase) were from the Project
ICARE (Intensive Care Antimicrobial Resistance
Epidemiology) strain collection (1,11). The imipenem
MICs for the isolates and the study identification of their
hospital of origin are shown in Table 1.
Reference Susceptibility Testing Methods
The antimicrobial susceptibility profiles of the isolates
were determined by the broth microdilution method with
cation-adjusted Mueller-Hinton broth (BD Diagnostic
Systems [BDDS], Sparks, MD, USA), as described in the
National Committee for Clinical Laboratory Standards
(NCCLS, Wayne, PA, USA) (now known as the Clinical
and Laboratory Standards Institute [CLSI]) publication
M7-A6 (16). Disk diffusion was performed as described in
NCCLS document M2-A8 (17). Interpretations of MIC
and disk diffusion results were made by using CLSI docu-
ment M100-S15 (18).
Commercial Susceptibility Testing 
and Molecular Methods
The Etest method (AB Biodisk, Solna, Sweden) was
performed as described by the manufacturer with Mueller-
Hinton agar (BDDS); tests were interpreted at 18–20 h.
The MicroScan WalkAway (Dade MicroScan, Inc.), BD
Phoenix (BDDS), Sensititre AutoReader (Westlake, OH,
USA), VITEK Legacy (bioMérieux), and VITEK 2
(bioMérieux) systems were tested according to manufac-
turers’ protocols. The panels and cards used are listed in
Table 2. All systems were tested with inocula from the
same subculture. All strains for which the commercial
MIC results were discrepant with MIC results from the
broth microdilution reference method were retested by
using all methods.
The carbapenem inactivation assay was performed on
Mueller-Hinton agar with imipenem and meropenem disks
as described by Yigit et al. (1). Isoelectric focusing was
performed on crude lysates of isolates as previously
described (1,2).
For detection of blaKPC genes, a 489-bp internal gene
fragment was amplified by using forward (5′-CTTGCT-
GCCGCTGTGCTG-3′) and reverse (5′-GCAGGTTCCG-
GTTTTGTCTC-3′) oligonucleotide primers where the 5′
base of each primer corresponds to position 223 or 711,
respectively, with regard to the translational start site
(blaKPC-1 numbering, GenBank accession no. AF297554).
PCR reagents included a final concentration of 0.5 µmol/L
of each primer and 2 mmol/L MgCl2. An annealing tem-
perature of 60°C was used for amplification.
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uct that included the entire blaKPC structural gene was
amplified by using oligonucleotide primers as previously
described (4). Products were purified on QIAquick spin
columns (Qiagen, Chatsworth, CA, USA). The nucleotide
sequences of both strands of the blaKPC gene from isolates
4 and 11 were determined from independent amplification
products by using previously described primers (1). Cycle
sequencing reactions were performed in a GeneAmp PCR
system 9700 thermal cycler with the ABI BigDye
Terminator v3.1 cycle sequencing kit (Perkin-Elmer,
Applied Biosystems Division, Foster City, CA, USA).
Products from sequencing reactions were purified on
Cetri-Sep spin columns (Princeton Separations, Adelphia,
NJ, USA) before analysis on an ABI 3130xl Genetic
Analyzer. DNA sequencing data were analyzed by using
DNASIS for Windows (Hitachi Software Genetic Systems,
San Francisco, CA, USA).
Results
Carbapenem Testing with VITEK Legacy
Initial imipenem and meropenem susceptibility test
results for 15 isolates of K. pneumoniae tested with the
VITEK Legacy system with GNS 122 and 127 panels (flex
system) in 1 hospital laboratory in New York City in a 1-
month period in 2005 yielded a range of imipenem and
meropenem MICs from susceptible (MIC <4 µg/mL) to
resistant (MIC >16 µg/mL) (data not shown). One isolate
was imipenem resistant (MIC >16 µg/mL) but meropenem
susceptible (<4 µg/mL) on day 1, but on retesting the fol-
lowing day was meropenem resistant (16 µg/mL) and
imipenem susceptible (<4 µg/mL). Imipenem Etest results,
which were set up to arbitrate the conflicting results, were
difficult to interpret because of variable numbers of
colonies within the ellipses of inhibition (Figure). A car-
bapenem inactivation assay performed on 1 isolate indicat-
ed that it contained a carbapenem-inactivating enzyme
(data not shown). The 15 isolates, which were collected
from 4 different hospitals in New York City, were sent to
the Centers for Disease Control and Prevention (Atlanta,
GA, USA) for additional testing.
Characterization of blaKPC-containing K. pneumoniae
Strains
By using the broth microdilution reference method, all
the isolates were either intermediate or resistant to both
imipenem and meropenem (Table 2). Two known imipen-
em-resistant isolates, K. pneumoniae 1534 and S.
marcescens 525, were included as controls. Eight of 15
isolates from the 4 hospitals had the same pulsed-field gel
electrophoresis (PFGE) type (data not shown), although
their antibiograms varied for several antimicrobial agents
(data not shown). Two isolates had a similar pattern but
because of a 3-band difference were designated as type B.
The remaining isolates showed patterns unrelated to types
A or B (Table 1). All 15 isolates demonstrated 5 β-lacta-
mase bands by isoelectric focusing (pIs = 5.4, 6.8, 7.0, 8.1,
and 8.2), 1 of which was consistent with a KPC β-lacta-
mase (pI = 6.8) (1,2). A 489-bp gene fragment was ampli-
fied from all 15 carbapenem-resistant K. pneumoniae
isolates by using blaKPC-specific oligonucleotide primers.
DNA sequence analysis of purified PCR products that
included the entire coding region of the blaKPC genes of
isolates 4 and 11 (which had unique PFGE profiles) iden-
tified the β-lactamase genes as blaKPC-2 and  blaKPC-3,
respectively.
The 15 isolates were tested for imipenem and meropen-
em resistance by disk diffusion, Etest, MicroScan
WalkAway, BD Phoenix, Sensititre AutoReader, VITEK,
and VITEK 2 panels and cards. The results of testing are
summarized in Table 2. MicroScan WalkAway reported 1
isolate as susceptible to both imipenem and meropenem,
whereas the Phoenix system called 2 isolates susceptible to
both imipenem and meropenem. VITEK called 7 isolates
(representing 3 different PFGE profiles) susceptible to both
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but susceptible to meropenem, 1 isolate susceptible to
imipenem but resistant to meropenem, and 2 isolates sus-
ceptible to imipenem but intermediate to meropenem. Of
the final 2 isolates, 1 was resistant to imipenem and inter-
mediate to meropenem, and the other was resistant to both
antimicrobial agents. Thus, 10 (67%) of 15 isolates were
interpreted on initial testing as susceptible to imipenem,
and 10 were susceptible to meropenem. When the VITEK
2 system was used, 5 (33%) of 15 isolates were reported as
susceptible to imipenem. The VITEK 2 Advanced Expert
System (AES) used the imipenem results to predict
meropenem results; thus, these same 5 isolates were called
meropenem susceptible. In addition, as a result of the
AES’s recognizing unusual susceptibility results in the
antibiograms of 2 K. pneumoniae isolates, AES did not
report an interpretation for meropenem for 2 isolates.
Finally, the VITEK 2 reported 2 isolates as imipenem
resistant and 1 isolate as imipenem intermediate, although
the MICs reported by AES were listed as <2 µg/mL. Aside
from these, all AES categorical interpretations were in
agreement with the original VITEK 2 MIC results.
When Sensititre panels were used, 10 (67%) of 15 iso-
lates were reported as susceptible to both imipenem and
meropenem, 2 isolates were reported as imipenem interme-
diate and meropenem susceptible, and 3 isolates were
reported as imipenem susceptible and meropenem interme-
diate. Thus, on initial testing, 13 (87%) of 15 isolates were
reported as imipenem susceptible, and 12 (80%) of 15 were
meropenem susceptible. Repeat testing of strain 4 yielded
imipenem- and meropenem-resistant results for MicroScan,
BD Phoenix, VITEK Legacy, and VITEK 2. However, the
Sensititre AutoReader results showed the isolate as suscep-
tible to imipenem and meropenem. Retesting of strain 14
on the BD Phoenix showed the isolate as resistant to
imipenem and meropenem. However, with VITEK Legacy,
the isolate remained susceptible to imipenem, but the
response to meropenem switched from 8 µg/mL (interme-
diate) to <4  µg/mL (susceptible), which confirmed the
observations of flip-flopping (i.e., reversing) results from
the New York City laboratory. The Sensititre AutoReader
results for strain 14 remained susceptible on repeat testing;
MicroScan results remained resistant.
Discussion
Detecting KPC-mediated carbapenem resistance in K.
pneumoniae isolates remains a challenge for many auto-
mated susceptibility testing systems. Although we used a
total of only 17 isolates in this study (including 1 S.
marcescens and 1 K. pneumoniae control), the isolates and
controls represented 4 different carbapenemases (KPC-1,
KPC-2, KPC-3, and an SME-like β-lactamase), 7 PFGE
types, and variable imipenem and meropenem resistance
profiles. Indeed, an important observation of this study is
that the carbapenem-resistance profiles of the isolates var-
ied from day to day, sometimes reversing from imipenem
resistant/ meropenem susceptible to imipenem suscepti-
ble/meropenem resistant.  Although in our study the
MicroScan and BD Phoenix systems produced results that
were more consistent with those with the reference testing
systems than those with the VITEK and Sensititre
AutoReader systems, problems detecting carbapenem
resistance were still evident with the former systems. Bratu
et al. suggested that part of the variability in detecting
imipenem resistance with automated systems was a result
of underinoculating the panels (14,15). Repeat testing of
isolate 4 in our study with careful attention to inoculum
appeared to improve results, which suggests that appropri-
ate inoculum size is, indeed, a critical factor for achieving
accurate results. The problem of the VITEK 2 AES report-
ing imipenem-resistant results as <2 µg/mL has apparently
been corrected in software version R04.02.
Although we included the Etest method in our study,
determining resistance and susceptibility for both imipen-
em and meropenem with Etest was difficult because
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Figure. Klebsiella pneumoniae isolate tested with imipenem Etest
strip (AB Biodisk, Solna, Sweden) on Mueller-Hinton agar. Inner
colonies made determination of the imipenem MIC difficult.colonies were present within the zones of inhibition. Since
we could not achieve consensus on the interpretations
among several readers who viewed the results, we did not
include the Etest data in our analysis. Ertapenem Etest
strips and disks were not tested in this study. This lack of
consensus on reading Etest method, which is often used as
a secondary testing method to confirm questionable results
generated by automated methods, raises the question of
which, if any, of the methods are reliable enough to be used
for confirmation testing of carbapenem nonsusceptibility,
particularly in K. pneumoniae isolates. Our data suggest
that disk diffusion, especially with meropenem disks, may
be used to confirm a carbapenem nonsusceptible result in
K. pneumoniae isolates, which would warrant further test-
ing. Whether this recommendation will hold true for other
species of Enterobacteriaceae will require further study.
Our data also suggest that if the interpretations of MIC or
disk diffusion results for imipenem and meropenem for K.
pneumoniae are discrepant, isolates should be retested with
particular attention to using an adequate inoculum size. If
treatment failure with carbapenems is observed for isolates
of K. pneumoniae that were previously reported as suscep-
tible to carbapenems, repeat testing with a nonautomated
method, such as disk diffusion, may be warranted.
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